INTRODUCTION
Worldwide, lung cancer occurred in approximately 1.8 million patients in 2012 representing 13% of all new cancer cases) and caused an estimated 1.6 million deaths, lung cancer has the highest mortality rate worldwide . 6 In the United States, there will be approximately 234,000 new cases of lung cancer and over 154,000 deaths annually. 18 In Egypt ,The lung cancer incidence is about 4.6% of all cancers in both sexes, representing about 6.9% of male cancers (5017 cases) and 2.5% of female cancers (3634 cases) and mortality rate 6.8% in males and 3.8% in females (Globocan fact sheet, Egypt 2012).Lung cancer deaths in Egypt reached 4,429 per 100,000 of population in 2002 . 3 Platinum-based chemotherapy remains the standardof-care for most patients affected by advanced non small cell lung cancer (NSCLC) , Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. 3 After the era of advances in the molecular biology, many mutations had been discovered in lung cancers cells, these mutations are currently drive the choice of first line treatment targeted therapy in such patients after the statistical significant survival and clinical benefits with high acceptable toxicity profile that had observed with the use of this class of therapy when compared with chemotherapy as first line treatment 17 Recently, the use of immune therapy in the first line treatment either alone or in combination with chemotherapy in selected patients with PDL-1 expression showed a significant superior progression-free survival (PFS) and OS when compared with standard chemotherapy alone. Therefore, the Key-note 024 trial was prematurely stopped in order to allow patients receiving Authorship: All authors have a substantial contributions to the article. Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors. chemotherapy to cross over to the immunotherapy arm. 13 The primary objective of this study is to assess the outcome of treatment in patients who presented with metastatic non-small cell lung cancer in term of response to treatment, treatment related toxicity, progression free survival and overall survival.
PATIENT AND METHODS
This Retrospective study included 56 patients with metastatic non-small cell lung cancer who received systemic treatment at our department during the period between June 1st 2012 and June 1st 2017, and meet the following inclusion criteria; histopathology confirming non-small cell lung cancer either histologically or cytological, age younger than 80 years old, Performance status 0-3 (WHO) and radiological confirmed distant metastases at presentation.
Charts of included patients have been retrieved from the archive to collect the following data: Age, sex, special habits (eg. smoking)، comorbidity, performance status, histopathology, chemotherapy related details, radiotherapy if received, and finally response to treatment according to RECIST criteria.
Overall survival interval was considered as the period between the date of histological diagnosis and the date of the last follow-up (for censored observations) or the date of death (for uncensored observations), while progression free interval was considered as the period between date of the first treatment and the date of the last follow-up (for censored observations), or date of death or disease progression whichever happen first (for uncensored observations).
Statistical methods:
Data were coded and entered using the statistical package SPSS version 23. Data was summarized using mean, standard deviation, median, minimum and maximum for quantitative variables and frequencies (number of cases) and relative frequencies (percentages) for categorical variables. One-sided log-rank of Kaplan-Meier survival estimates was used for statistical analysis of overall survival and progression free survival, while the unpaired T test and one-way ANOVA test were used in the univariate analysis of the variables. Results of P-values less than 0.05 were considered as statistically significant.
Ethical approval:
The current investigation was had been executed based on the recommendations approved by the ethical committee, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, before the start of this study.
RESULTS
In the study group, the mean age of the 56 included patients was 57.9 (±10.3), male patients were 44 (78.6 %) , and females were 12 (21.4 %), with male to female ratio 3 The median progression free survival was 8.9 months for all patients included in this study, however it was 9.3 and 7.5 months for patients who received chemotherapy and didn't receive any treatment respectively, with no statistical difference between the two group (P= 0.3). Figure ( Up to this moment the targeted therapy not provided by the Egyptian health ministry to none insured patients, that represent the majority patients receiving treatment at our department, because of this the overall survival in the patients included in our study is considered very low compared to the published data in the era of targeted therapy 19 With stage IV disease who have a good PS benefit from chemotherapy, usually with a platinum-based regimen is recommended for patients with stage IV NSCLC and negative or unknown test results for ALK rearrangements or sensitizing EGFR mutations, PD-L1 expression less than 1% or unknown and contraindications to immunotherapy. Recommended chemotherapy regimens are based on PS and include platinum agents (eg, cisplatin carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel [also known as nab-paclitaxel], docetaxel), vinorelbine, etoposide, pemetrexed, and gemcitabine . 4 Patients included in our study received platinum based chemotherapy mean No of cycles were 4 range (1-9) and radiotherapy used as palliative treatment for symptomatic patients that similar to published data reported that Chemotherapy improves both survival and quality of life in metastatic NSCLC, four cycles of platinum based Chemotherapy (max 6 cycles) is the standard treatment for patient with good Performance status. Patients with border line Performance status =2 may benefit from single agent. Palliative radiotherapy is introduced for symptomatic patients only 22 , Four to six cycles of platinum based chemotherapy is indicated in patients with metastatic non small cell lung cancer with good performance status , Extending the duration of treatment with the initial platinum based chemotherapy beyond four to six cycles is not recommended 4 In our study we considered grades 2-4 toxicities of chemotherapy among who received chemotherapy , 15 In our study group the progression free survival (PFS) had no significant difference between patients who received chemotherapy and those who didn't receive any treatment median PFS was 9.3 months (7.1-11.4 ) for patients who received chemotherapy and 7.5 months (1.8-13.1) ( P = 0.349) for patients who didn't receive any treatment that was different with data published by 14 Unfortunately none of our patients received pemetrexed in their treatment due to unavailability of treatment ,that's why we couldn't assess survival on adding pemetrexed to chemotherapy regimens , on the other hand A phase III trial in which Survival in the 847 patients with adenocarcinoma was significantly prolonged with cisplatin plus pemetrexed compared with cisplatin plus gemcitabine (median 12.6 versus 10.9 months respectively). 21 In our study group median OS was 10.8(3.7-17.9) months in patients didn't receive active treatment versus 13.6 months (9.3-17.9) in patients received chemotherapy (p value 0.019 ) that was similar to results of data published in(2001) 1 who reported median OS was ( 13.7 months ) (range 7.4 -213 weeks ) (p=0.0018).in patients who received chemotherapy) , and different from results of study published in 2016 . 20 The use of immune therapy in the first line treatment either alone or in combination with chemotherapy in selected patients with PDL-1 expression showed a significant superior progression-free survival (PFS) and OS when compared with standard chemotherapy alone. Therefore, according to ESMO guidelines patients of (KEYNOTE-024 trial was prematurely stopped receiving chemotherapy to cross over to the immunotherapy arm . 13 Unfortunately Up to this moment immune therapy not provided by the Egyptian health ministry to none insured patients, that represent the majority patients receiving treatment at our department so our patients couldn't gain benefit of such treatment option .
CONCLUSION
In patients with metastatic NSCLC, if molecular tests of gene mutations and checkpoints expressions not available, a four to six cycles of platinum based chemotherapy is indicated in patients with good performance status as regard that chemotherapy showed survival benefit versus best supportive care. 
